Purpose: This study examined the effects of longterm pre-exercise Curcuma xanthorriza Roxb supplementation on red blood cell indices along with circulating malondialdehyde (MDA) and superoxide dismutase (SOD) levels in response to endurance exercise to address previously inconsistent findings.
Methods: Male Wistar rats (Rattus norvegicus; n = 20, aged 12-16 weeks) were divided equally into an exercise-only group (C) and three groups supplemented with Curcuma extract at dosages of 6.75 (T1), 13.50 (T2), and 20.25 mg (T3). Curcuma extract supplementation was administered for 28 d immediately prior to exercise.
Results: Following 28 d of exhaustive swimming, the hematocrit and erythrocyte count increased by 15% (p = 0.06). Pre-exercise Curcuma supplementation did not significantly affect mean corpuscular volume or mean corpuscular hemoglobin concentration. Longterm exercise intervention resulted in elevated MDA levels by 41% (p <0.001), while Curcuma supplementation (13.50 mg) attenuated this increase by 16.6% (p = 0.09). Additionally, Curcuma supplementation resulted in a dose-dependent increase in SOD levels, with an 82.6% increase observed at 20.25 mg (p = 0.028).
Conclusion: Our preliminary findings indicated that pre-exercise supplementation with Curcuma extract had a negligible effect on changes in red blood cell markers, but it mitigated the increase in oxidative stress induced by exercise training. Our future research direction will involve applying the findings to humans.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540990 | PMC |
http://dx.doi.org/10.20463/pan.2024.0023 | DOI Listing |
Eur J Trauma Emerg Surg
January 2025
Intensive Care Department, Sainte Anne Military Teaching Hospital, Toulon, France.
Background: Haemorrhagic shock is the leading cause of preventable death among trauma patients. Early detection of severe haemorrhage is essential for initiating timely resuscitation and mobilizing resources for massive transfusion (MT) protocols and damage control procedures. This study aimed to assess the predictive value of prehospital haemoglobin (Hb) levels for the need for transfusion at admission, the presence of haemorrhagic shock (HS), and the necessity for MT or haemostatic surgery.
View Article and Find Full Text PDFBreast Cancer (Auckl)
January 2025
Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Background: Circulating rare cells participate in breast cancer evolution as systemic components of the disease and thus, are a source of theranostic information. Exploration of cancer-associated rare cells is in its infancy.
Objectives: We aimed to investigate and classify abnormalities in the circulating rare cell population among early-stage breast cancer patients using fluorescence marker identification and cytomorphology.
Extracorporeal Membrane Oxygenation (ECMO) serves as a crucial intervention for patients with severe pulmonary dysfunction by facilitating oxygenation and carbon dioxide removal. While traditional ECMO systems are effective, their large priming volumes and significant blood-contacting surface areas can lead to complications, particularly in neonates and pediatric patients. Microfluidic ECMO systems offer a promising alternative by miniaturizing the ECMO technology, reducing blood volume requirements, and minimizing device surface area to improve safety and efficiency.
View Article and Find Full Text PDFCureus
December 2024
Department of Internal Medicine, Bursa Uludag University, Bursa, TUR.
Introduction Multiple myeloma (MM) is a complex plasma cell malignancy characterized by clonal proliferation and monoclonal immunoglobulin production. Despite the availability of several prognostic markers for MM, many are challenging to implement routine clinical practice due to cost, complexity, or lack of standardization. Red cell distribution width (RDW), a cost-effective and routinely measured parameter in complete blood counts, has gained increasing attention as a prognostic marker due to its association with disease severity and outcomes in MM.
View Article and Find Full Text PDFGastroenterology Res
December 2024
Division of Medical Oncology, Department of Internal Medicine, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Background: Immune checkpoint inhibitors (ICIs) have moved to the frontline in recent years to manage upper gastrointestinal (UGI) tumors, such as esophageal and gastric cancers. This retrospective review sheds light on real-world data on ICI-treated UGI tumors to identify risk factors (clinical and pathological) impacting the outcome other than traditional biomarkers (programmed cell death ligand 1 (PD-L1) or microsatellite instability status).
Methods: Patients with UGI tumors who received at least one dose of ICI for stage IV or recurrent disease between January 1, 2015, and July 31, 2021, at The Ohio State University were included in the study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!